Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes.
about
A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistencyImproved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapyPilot study of an interactive voice response system to improve medication refill complianceUpdated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.The value of irbesartan in the management of hypertension.Common secondary causes of resistant hypertension and rational for treatmentCombined aliskiren and L-arginine treatment has antihypertensive effects and prevents vascular endothelial dysfunction in a model of renovascular hypertension.Predictors of blood pressure response in the SYMPLICITY HTN-3 trialA review of studies of adherence with antihypertensive drugs using prescription databases.First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination.Predictors of decline in medication adherence: results from the cohort study of medication adherence among older adults.Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review.Olmesartan medoxomil: current status of its use in monotherapy.Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review.Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?Optimizing hypertension management in clinical practice.From hypertension to heart failure -- are there better primary prevention strategies?Antihypertensive agents and renal transplantation.Predictors of self-reported noncompliance with antihypertensive drug treatment: a prospective cohort study.Cohort study of medication adherence in older adults (CoSMO): extended effects of Hurricane Katrina on medication adherence among older adults.Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementiaBlood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.Medication adherence and persistence in severe obstructive sleep apneaThe influence of targeted education on medication persistence and generic substitution among consumer-directed health care enrollees.Short- and long-term use of medication for psychological distress after the diagnosis of cancer.Postmarketing surveillance study of benazepril in chinese patients with hypertension: An open-label, experimental, epidemiologic study.Cardiovascular consequences of poor compliance to antihypertensive therapy.Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.Angiotensin receptor blockers in clinical practice--implications of the ONTARGET study.What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels? Pro and Cons.Changes in the continuation of antihypertensive drug use after ALLHAT.Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment.Discontinuation of angiotensin-converting enzyme inhibitors: a cohort study.Long-term persistence to mono and combination therapies with angiotensin converting enzymes and angiotensin II receptor blockers in Australia.Level of hypertension control: comparison of a rural and urban family practice centre in South Croatia.The efficacy and safety of valsartan in obese and non-obese pediatric hypertensive patients.The association between market availability and adherence to antihypertensive medications: an observational study.Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension.The impact of cardiovascular profile on persistence associated with antihypertensive medications.
P2860
Q30430605-F7E962CE-C76D-48EA-AF5D-40D087776E1DQ30850706-C97CE272-8DD1-428A-9F77-001ED70FBDC3Q33374875-4DB6ED86-04DD-4322-9263-5EA176FAB2E4Q34093100-E2AA08E5-6ED3-4E71-A863-3548910BA80FQ34609900-3685D1EC-8978-40A1-935B-70100FEE3E58Q34669789-1D427528-5578-488C-91AB-39AA4FCAE76DQ34886548-2929BCA0-32C0-458E-8C63-3959F74EA24FQ34994094-60215292-5E2C-4893-98F6-44E5E7C9C26CQ35166678-00A76553-F4E0-4502-A63B-1312D8F90ADDQ35210508-3985E144-F5C9-4444-A882-40512A11A1D2Q35563068-DD9289C0-9856-4969-9F80-6BB4F7CEFA41Q35999686-BB7916E3-3082-4B98-9CE1-A28797B976C6Q36013054-9AF33D3A-A480-41B1-BE7C-6516520B86A1Q36242608-972B5225-743A-4263-8D8D-6D90683C963FQ36432150-8CD5748F-6698-4B84-AD1A-3E01C31F1092Q36541439-FB73A7AA-466D-41E8-AB1D-10031BD5B7FAQ36568468-FD67F14D-B8B0-47B6-BD72-0D8EECA13976Q36643663-D1226ADE-D7BE-4AD3-93FE-456830BC3DD4Q36765942-3E9C1986-9B77-472B-ACD5-245ECB44EDFEQ36921060-1F0B0557-0C1B-42DC-96A7-E9E7D379019CQ36922751-8B2BD700-5DBC-48B5-A56B-8CD81ACC87C3Q36989228-5CB2CA91-C4C1-49CB-8A37-527742BF20BFQ37159292-7F526E75-22F0-441E-AE89-B8352CDA4E34Q37176067-66B61E1A-6328-41D8-9AC8-541CF8617B30Q37485242-0C3CCA56-DC8B-47CA-911A-E8F10169966CQ37607289-EFC6D2EE-8C7D-41BC-9AC6-D5C30CBBE02BQ37661046-87903A35-157B-447A-8331-B1C1F407ABF6Q37836893-870FDFA2-CFDA-4E37-AC7C-8F9DE35AC2D4Q37960888-03AF7A1C-7D90-4E87-BE21-99EFDA868BCCQ37994859-FD735D81-3B1D-4C04-B8B5-65F1EC739E5EQ38071013-E4334844-C41B-4E00-B2CA-A75C72C68B7DQ38471032-055E8E66-DAB3-40B9-AA1F-AD508C8A8321Q39427698-4B2FA053-1B18-42AE-A1DB-7ED819DABAA0Q39694133-7771199E-9D65-471F-AA63-AFF0D8F8739EQ39933900-63402A71-0D5C-4C56-940F-0558BF9C9B54Q40099153-823AE2EE-DA46-492E-A128-FE54DA44C4E2Q40310246-649972D3-36A0-436B-A5F1-CEF3388612D9Q43973075-BC739A0D-A720-42F6-997D-CA568705F94EQ46227448-64F5A5BC-72E3-4FA5-B53F-516A70083406Q46987409-6E1D1B09-D8B5-4788-957B-942098A67FFF
P2860
Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Four-Year persistence patterns ...... artihypertensive drug classes.
@en
Four-Year persistence patterns ...... artihypertensive drug classes.
@nl
type
label
Four-Year persistence patterns ...... artihypertensive drug classes.
@en
Four-Year persistence patterns ...... artihypertensive drug classes.
@nl
prefLabel
Four-Year persistence patterns ...... artihypertensive drug classes.
@en
Four-Year persistence patterns ...... artihypertensive drug classes.
@nl
P2093
P1476
Four-Year persistence patterns ...... artihypertensive drug classes.
@en
P2093
P304
P356
10.1016/S0149-2918(01)80152-1
P577
2001-12-01T00:00:00Z